Sign inJoin waitlistJoin the waitlist

Maha H. Hussain

Professor, Feinberg School of Medicine · Feinberg School of Medicine

Credentials: · · · · ·

History

Feinberg School of Medicine
Present

Wayne State University School of Medicine
Until 1989
Detroit Medical Center/Wayne State University
Until 1986
University of Baghdad College of Medicine
1980

Research

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
New England Journal of Medicine · 2004 · 3,019 citations
Integrative clinical genomics of advanced prostate cancer
Cell · 2015 · 2,800 citations
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
New England Journal of Medicine · 2015 · 2,355 citations

Cora Sternberg
42 papers
David Crawford
42 papers
Neeraj Agarwal
37 papers
MC
Michael Carducci
34 papers
NS
Neal Shore
34 papers
CH
Celestia Higano
33 papers
IT
Ian Thompson
33 papers · 10 as a resident
NV
Nicholas Vogelzang
33 papers
DS
David Smith
32 papers
MS
Matthew Smith
30 papers
CS
Christopher Sweeney
29 papers
Eric Small
29 papers

Grants

NU-TRIHO (Northwestern University Translational Research in Hematology-Oncology) Training Program
National Cancer Institute · T32
PI · $984.9K · Northwestern University
2023–2028
SPORE in Prostate Cancer
National Cancer Institute · P50
PI · $9M · Northwestern University
2015–2027
Michigan Prostate SPORE 2025-2030
National Cancer Institute · P50
Project lead · $540.9K · University of Michigan at Ann Arbor
2014–2019
In Vivo Imaging of Neoplasia
National Cancer Institute · P50
Project lead · $434.5K · University of Michigan at Ann Arbor
2008–2014

Clinical trials

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2019–2027
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Unknown · Phase 2
Northwestern University
2019–2022
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Principal investigator · Completed · Phase 3
AstraZeneca
2017–2023
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Principal investigator · Active not recruiting · Phase 2
Northwestern University
2017–2027